[{"id":6089,"regimens":[{"id":11488,"duration":{"id":5543,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":8102,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11488},{"id":8103,"answer":"In a novel combination with another drug","answer_other":"","regimen":11488}],"created":"2020-09-24T18:04:52.937013Z","updated":"2020-09-24T18:13:26.906706Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6089},{"id":11489,"duration":{"id":5544,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":8104,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11489},{"id":8105,"answer":"In a novel combination with another drug","answer_other":"","regimen":11489}],"created":"2020-09-24T18:04:52.944662Z","updated":"2020-09-24T18:13:26.913495Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6089},{"id":11490,"duration":{"id":5545,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11379,"name":"Baricitinib","url":"cure-api2.ncats.io/v1/drugs/11379","rxNorm_id":null,"notes":null},"use_drug":[{"id":8106,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":11490},{"id":8107,"answer":"In a novel combination with another drug","answer_other":"","regimen":11490}],"created":"2020-09-24T18:04:52.954274Z","updated":"2020-09-24T18:13:26.919407Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6089}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7994,"answer":"Clinical assessment","answer_other":"","report":6089}],"how_diagnosis":[{"id":13605,"answer":"Clinical assessment","answer_other":"","report":6089},{"id":13606,"answer":"Imaging","answer_other":"","report":6089},{"id":13607,"answer":"PCR","answer_other":"","report":6089}],"author_username":"Reema Charles","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"None","author_country":"","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4081,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6089}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[{"id":337,"answer":"White","answer_other":""}],"created":"2020-09-24T18:01:00.805558Z","updated":"2020-09-24T18:13:26.898860Z","title":"Baricitinib: A chance to treat COVID-19? Case 1","status":"Approved","anonymous":false,"published":true,"pubmed_id":32437019,"doi":"10.1002/jmv.26033","article_url":"https://pubmed.ncbi.nlm.nih.gov/32437019/","pub_year":2020,"published_authors":"Lo Caputo S\r\nCorso G\r\nClerici M\r\nSantantonio TA","article_author_email":"Author email could not be found.","journal":"Journal of medical virology","abstract":"Herein we report for the first time the favorable clinical course of a patient with a diagnosis of RA who had undergone baricitinib therapy for more than a year and who developed COVID‐19.\r\n\r\nThe patient, an 87‐year‐old woman, was admitted on March 10, to the Infectious Disease Unit, University Hospital of Foggia, Italy with a mild‐to‐moderate COVID‐19. The patient was part of a familiar cluster, as COVID‐19 was diagnosed in three other family members (husband, son, and daughter)","article_type":"Original","study_type":"Case Report","number_of_patients":4,"article_patient_number":"1","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"No","age":"81-89 years","sex":"Female","ethnicity":"Not Hispanic/Latino","country_contracted":"Italy","country_treated":"Italy","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"Rheumatoid arthritis","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Respiratory tract infection","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"The patient received supplemental oxygenation, lopinavir/ritonavir, hydroxychloroquine, while continuing baricitinib. Therapy was successful as she recovered: she is currently apyretic with O2 saturation 95% in ambient air.\r\n\r\nIn contrast, her husband (90‐year‐old) and son (59‐year‐old), who received the same therapy with the exception of baricitinib, showed a rapid disease progression and after few days they died of respiratory failure.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11379,8342,8783]},{"id":6621,"regimens":[{"id":13205,"duration":{"id":7095,"approximate_duration":"7 days","dates_unknown":true},"drug":{"id":11379,"name":"Baricitinib","url":"cure-api2.ncats.io/v1/drugs/11379","rxNorm_id":null,"notes":null},"use_drug":[{"id":11556,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13205},{"id":11557,"answer":"In a novel combination with another drug","answer_other":"","regimen":13205}],"created":"2020-12-01T00:50:07.527731Z","updated":"2020-12-02T21:10:10.129348Z","dose":"4 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6621},{"id":13206,"duration":{"id":7096,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8711,"name":"Levofloxacin","url":"cure-api2.ncats.io/v1/drugs/8711","rxNorm_id":null,"notes":null},"use_drug":[{"id":11558,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13206},{"id":11559,"answer":"In a novel combination with another drug","answer_other":"","regimen":13206}],"created":"2020-12-01T00:50:07.535591Z","updated":"2020-12-02T21:10:10.135669Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":6621},{"id":13207,"duration":{"id":7097,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11121,"name":"Vancomycin","url":"cure-api2.ncats.io/v1/drugs/11121","rxNorm_id":11124,"notes":""},"use_drug":[{"id":11560,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13207},{"id":11561,"answer":"In a novel combination with another drug","answer_other":"","regimen":13207}],"created":"2020-12-01T00:50:07.542266Z","updated":"2020-12-02T21:10:10.141325Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6621},{"id":13208,"duration":{"id":7098,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8783,"name":"Lopinavir-Ritonavir","url":"cure-api2.ncats.io/v1/drugs/8783","rxNorm_id":null,"notes":null},"use_drug":[{"id":11562,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13208},{"id":11563,"answer":"In a novel combination with another drug","answer_other":"","regimen":13208}],"created":"2020-12-01T00:50:07.548549Z","updated":"2020-12-02T21:10:10.146937Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6621},{"id":13209,"duration":{"id":7099,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11564,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13209},{"id":11565,"answer":"In a novel combination with another drug","answer_other":"","regimen":13209}],"created":"2020-12-01T00:50:07.554702Z","updated":"2020-12-02T21:10:10.152594Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6621}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8687,"answer":"Clinical assessment","answer_other":"","report":6621}],"how_diagnosis":[{"id":14929,"answer":"Clinical assessment","answer_other":"","report":6621},{"id":14930,"answer":"PCR","answer_other":"","report":6621}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4801,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6621}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-12-01T00:45:19.263567Z","updated":"2020-12-02T21:10:10.120784Z","title":"Use of Baricitinib in Patients with Moderate and Severe COVID-19. Case 1.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32597466,"doi":"10.1093/cid/ciaa879","article_url":"https://pubmed.ncbi.nlm.nih.gov/32597466/","pub_year":2020,"published_authors":"Titanji BK\r\nFarley MM\r\nMehta A\r\nConnor-Schuler R\r\nMoanna A\r\nCribbs SK\r\nO'Shea J\r\nDeSilva K\r\nChan B\r\nEdwards A\r\nGavegnano C\r\nSchinazi RF\r\nMarconi VC","article_author_email":"Author email could not be found.","journal":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","abstract":"Cytokine storm and hyperinflammation are associated with increased mortality in COVID-19. In this small uncontrolled cohort of patients with moderate-severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized controlled clinical trials.","article_type":"Original","study_type":"Case Report","number_of_patients":15,"article_patient_number":"1","full_text_available":true,"outcome":"Patient improved","surgery":"Unknown","age":"","sex":"","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, fever","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient experienced rhabdomyolysis and deep venous thrombosis of the upper right arm.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11379,8342,8711,8783,11121]},{"id":6622,"regimens":[{"id":13210,"duration":{"id":7100,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":11566,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13210},{"id":11567,"answer":"In a novel combination with another drug","answer_other":"","regimen":13210}],"created":"2020-12-01T01:02:15.220200Z","updated":"2020-12-02T21:09:21.071710Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6622},{"id":13211,"duration":{"id":7101,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11568,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13211},{"id":11569,"answer":"In a novel combination with another drug","answer_other":"","regimen":13211}],"created":"2020-12-01T01:02:15.227635Z","updated":"2020-12-02T21:09:21.078274Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6622},{"id":13212,"duration":{"id":7102,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":11379,"name":"Baricitinib","url":"cure-api2.ncats.io/v1/drugs/11379","rxNorm_id":null,"notes":null},"use_drug":[{"id":11570,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13212},{"id":11571,"answer":"In a novel combination with another drug","answer_other":"","regimen":13212}],"created":"2020-12-01T01:02:15.234051Z","updated":"2020-12-02T21:09:21.084242Z","dose":"4 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6622}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8688,"answer":"Clinical assessment","answer_other":"","report":6622}],"how_diagnosis":[{"id":14931,"answer":"Clinical assessment","answer_other":"","report":6622},{"id":14932,"answer":"PCR","answer_other":"","report":6622}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4802,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6622}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-12-01T01:01:13.768226Z","updated":"2020-12-02T21:09:21.063531Z","title":"Use of Baricitinib in Patients with Moderate and Severe COVID-19. Case 2.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32597466,"doi":"10.1093/cid/ciaa879","article_url":"https://pubmed.ncbi.nlm.nih.gov/32597466/","pub_year":2020,"published_authors":"Titanji BK\r\nFarley MM\r\nMehta A\r\nConnor-Schuler R\r\nMoanna A\r\nCribbs SK\r\nO'Shea J\r\nDeSilva K\r\nChan B\r\nEdwards A\r\nGavegnano C\r\nSchinazi RF\r\nMarconi VC","article_author_email":"Author email could not be found.","journal":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","abstract":"Cytokine storm and hyperinflammation are associated with increased mortality in COVID-19. In this small uncontrolled cohort of patients with moderate-severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized controlled clinical trials.","article_type":"","study_type":"Case Report","number_of_patients":15,"article_patient_number":"2","full_text_available":false,"outcome":"Patient was cured/recovered","surgery":"Unknown","age":"","sex":"","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, fever","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,11379,8342]},{"id":6623,"regimens":[{"id":13213,"duration":{"id":7103,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":11572,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13213},{"id":11573,"answer":"In a novel combination with another drug","answer_other":"","regimen":13213}],"created":"2020-12-01T01:07:57.635401Z","updated":"2020-12-02T21:11:36.870974Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6623},{"id":13214,"duration":{"id":7104,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11574,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13214},{"id":11575,"answer":"In a novel combination with another drug","answer_other":"","regimen":13214}],"created":"2020-12-01T01:07:57.642843Z","updated":"2020-12-02T21:11:36.877449Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6623},{"id":13215,"duration":{"id":7105,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":11379,"name":"Baricitinib","url":"cure-api2.ncats.io/v1/drugs/11379","rxNorm_id":null,"notes":null},"use_drug":[{"id":11576,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13215},{"id":11577,"answer":"In a novel combination with another drug","answer_other":"","regimen":13215}],"created":"2020-12-01T01:07:57.649737Z","updated":"2020-12-02T21:11:36.883070Z","dose":"4 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6623}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8689,"answer":"Clinical assessment","answer_other":"","report":6623}],"how_diagnosis":[{"id":14933,"answer":"Clinical assessment","answer_other":"","report":6623},{"id":14934,"answer":"PCR","answer_other":"","report":6623}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4803,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6623}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-12-01T01:07:15.925451Z","updated":"2020-12-02T21:11:36.863281Z","title":"Use of Baricitinib in Patients with Moderate and Severe COVID-19. Case 3.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32597466,"doi":"10.1093/cid/ciaa879","article_url":"https://pubmed.ncbi.nlm.nih.gov/32597466/","pub_year":2020,"published_authors":"Titanji BK\r\nFarley MM\r\nMehta A\r\nConnor-Schuler R\r\nMoanna A\r\nCribbs SK\r\nO'Shea J\r\nDeSilva K\r\nChan B\r\nEdwards A\r\nGavegnano C\r\nSchinazi RF\r\nMarconi VC","article_author_email":"Author email could not be found.","journal":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","abstract":"Cytokine storm and hyperinflammation are associated with increased mortality in COVID-19. In this small uncontrolled cohort of patients with moderate-severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized controlled clinical trials.","article_type":"Original","study_type":"Case Report","number_of_patients":15,"article_patient_number":"3","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"Unknown","age":"","sex":"","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, fever","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,11379,8342]},{"id":6624,"regimens":[{"id":13216,"duration":{"id":7106,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11578,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13216},{"id":11579,"answer":"In a novel combination with another drug","answer_other":"","regimen":13216}],"created":"2020-12-01T01:13:27.521848Z","updated":"2020-12-02T21:12:33.110191Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6624},{"id":13217,"duration":{"id":7107,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":11379,"name":"Baricitinib","url":"cure-api2.ncats.io/v1/drugs/11379","rxNorm_id":null,"notes":null},"use_drug":[{"id":11580,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13217},{"id":11581,"answer":"In a novel combination with another drug","answer_other":"","regimen":13217}],"created":"2020-12-01T01:13:27.530254Z","updated":"2020-12-02T21:12:33.116656Z","dose":"2 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6624}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8690,"answer":"Clinical assessment","answer_other":"","report":6624}],"how_diagnosis":[{"id":14935,"answer":"Clinical assessment","answer_other":"","report":6624},{"id":14936,"answer":"PCR","answer_other":"","report":6624}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4804,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6624}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-12-01T01:12:09.148506Z","updated":"2020-12-02T21:12:33.102462Z","title":"Use of Baricitinib in Patients with Moderate and Severe COVID-19. Case 4.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32597466,"doi":"10.1093/cid/ciaa879","article_url":"https://pubmed.ncbi.nlm.nih.gov/32597466/","pub_year":2020,"published_authors":"Titanji BK\r\nFarley MM\r\nMehta A\r\nConnor-Schuler R\r\nMoanna A\r\nCribbs SK\r\nO'Shea J\r\nDeSilva K\r\nChan B\r\nEdwards A\r\nGavegnano C\r\nSchinazi RF\r\nMarconi VC","article_author_email":"Author email could not be found.","journal":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","abstract":"Cytokine storm and hyperinflammation are associated with increased mortality in COVID-19. In this small uncontrolled cohort of patients with moderate-severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized controlled clinical trials.","article_type":"Original","study_type":"Case Report","number_of_patients":15,"article_patient_number":"4","full_text_available":true,"outcome":"Patient was cured/recovered","surgery":"Unknown","age":"","sex":"","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, fever","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"This patient experienced an acute kidney injury while hospitalized.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11379,8342]},{"id":6625,"regimens":[{"id":13218,"duration":{"id":7108,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":11582,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13218},{"id":11583,"answer":"In a novel combination with another drug","answer_other":"","regimen":13218}],"created":"2020-12-01T01:18:25.443391Z","updated":"2020-12-02T21:13:43.103248Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6625},{"id":13219,"duration":{"id":7109,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11584,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13219},{"id":11585,"answer":"In a novel combination with another drug","answer_other":"","regimen":13219}],"created":"2020-12-01T01:18:25.451545Z","updated":"2020-12-02T21:13:43.109580Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6625},{"id":13220,"duration":{"id":7110,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":11379,"name":"Baricitinib","url":"cure-api2.ncats.io/v1/drugs/11379","rxNorm_id":null,"notes":null},"use_drug":[{"id":11586,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13220},{"id":11587,"answer":"In a novel combination with another drug","answer_other":"","regimen":13220}],"created":"2020-12-01T01:18:25.458173Z","updated":"2020-12-02T21:13:43.115225Z","dose":"4 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6625}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8691,"answer":"Clinical assessment","answer_other":"","report":6625}],"how_diagnosis":[{"id":14937,"answer":"Clinical assessment","answer_other":"","report":6625},{"id":14938,"answer":"PCR","answer_other":"","report":6625}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4805,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6625}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-12-01T01:17:54.604917Z","updated":"2020-12-02T21:13:43.095535Z","title":"Use of Baricitinib in Patients with Moderate and Severe COVID-19. Case 5.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32597466,"doi":"10.1093/cid/ciaa879","article_url":"https://pubmed.ncbi.nlm.nih.gov/32597466/","pub_year":2020,"published_authors":"Titanji BK\r\nFarley MM\r\nMehta A\r\nConnor-Schuler R\r\nMoanna A\r\nCribbs SK\r\nO'Shea J\r\nDeSilva K\r\nChan B\r\nEdwards A\r\nGavegnano C\r\nSchinazi RF\r\nMarconi VC","article_author_email":"Author email could not be found.","journal":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","abstract":"Cytokine storm and hyperinflammation are associated with increased mortality in COVID-19. In this small uncontrolled cohort of patients with moderate-severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized controlled clinical trials.","article_type":"Original","study_type":"Case Report","number_of_patients":15,"article_patient_number":"5","full_text_available":true,"outcome":"Patient improved","surgery":"Unknown","age":"","sex":"","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, fever","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,11379,8342]},{"id":6626,"regimens":[{"id":13221,"duration":{"id":7111,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":11588,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13221},{"id":11589,"answer":"In a novel combination with another drug","answer_other":"","regimen":13221}],"created":"2020-12-01T01:24:11.677639Z","updated":"2020-12-02T21:38:01.404934Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6626},{"id":13222,"duration":{"id":7112,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11590,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13222},{"id":11591,"answer":"In a novel combination with another drug","answer_other":"","regimen":13222}],"created":"2020-12-01T01:24:11.685720Z","updated":"2020-12-02T21:38:01.411407Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6626},{"id":13223,"duration":{"id":7113,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":11379,"name":"Baricitinib","url":"cure-api2.ncats.io/v1/drugs/11379","rxNorm_id":null,"notes":null},"use_drug":[{"id":11592,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13223},{"id":11593,"answer":"In a novel combination with another drug","answer_other":"","regimen":13223}],"created":"2020-12-01T01:24:11.692122Z","updated":"2020-12-02T21:38:01.417121Z","dose":"4 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6626}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8692,"answer":"Clinical assessment","answer_other":"","report":6626}],"how_diagnosis":[{"id":14939,"answer":"Clinical assessment","answer_other":"","report":6626},{"id":14940,"answer":"PCR","answer_other":"","report":6626}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4806,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6626}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-12-01T01:22:49.566529Z","updated":"2020-12-02T21:38:01.396884Z","title":"Use of Baricitinib in Patients with Moderate and Severe COVID-19. Case 6.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32597466,"doi":"10.1093/cid/ciaa879","article_url":"https://pubmed.ncbi.nlm.nih.gov/32597466/","pub_year":2020,"published_authors":"Titanji BK\r\nFarley MM\r\nMehta A\r\nConnor-Schuler R\r\nMoanna A\r\nCribbs SK\r\nO'Shea J\r\nDeSilva K\r\nChan B\r\nEdwards A\r\nGavegnano C\r\nSchinazi RF\r\nMarconi VC","article_author_email":"Author email could not be found.","journal":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","abstract":"Cytokine storm and hyperinflammation are associated with increased mortality in COVID-19. In this small uncontrolled cohort of patients with moderate-severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized controlled clinical trials.","article_type":"Original","study_type":"Case Report","number_of_patients":15,"article_patient_number":"6","full_text_available":true,"outcome":"Patient improved","surgery":"Unknown","age":"","sex":"","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, fever","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,11379,8342]},{"id":6627,"regimens":[{"id":13224,"duration":{"id":7114,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11594,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13224},{"id":11595,"answer":"In a novel combination with another drug","answer_other":"","regimen":13224}],"created":"2020-12-01T01:29:19.910707Z","updated":"2020-12-02T21:39:02.219811Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6627},{"id":13225,"duration":{"id":7115,"approximate_duration":"1 day","dates_unknown":true},"drug":{"id":11379,"name":"Baricitinib","url":"cure-api2.ncats.io/v1/drugs/11379","rxNorm_id":null,"notes":null},"use_drug":[{"id":11596,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13225},{"id":11597,"answer":"In a novel combination with another drug","answer_other":"","regimen":13225}],"created":"2020-12-01T01:29:19.918828Z","updated":"2020-12-02T21:39:02.226304Z","dose":"4 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6627}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14941,"answer":"Clinical assessment","answer_other":"","report":6627},{"id":14942,"answer":"PCR","answer_other":"","report":6627}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4807,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6627}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-12-01T01:28:56.164216Z","updated":"2020-12-02T21:39:02.211380Z","title":"Use of Baricitinib in Patients with Moderate and Severe COVID-19. Case 7.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32597466,"doi":"10.1093/cid/ciaa879","article_url":"https://pubmed.ncbi.nlm.nih.gov/32597466/","pub_year":2020,"published_authors":"Titanji BK\r\nFarley MM\r\nMehta A\r\nConnor-Schuler R\r\nMoanna A\r\nCribbs SK\r\nO'Shea J\r\nDeSilva K\r\nChan B\r\nEdwards A\r\nGavegnano C\r\nSchinazi RF\r\nMarconi VC","article_author_email":"Author email could not be found.","journal":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","abstract":"Cytokine storm and hyperinflammation are associated with increased mortality in COVID-19. In this small uncontrolled cohort of patients with moderate-severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized controlled clinical trials.","article_type":"Original","study_type":"Case Report","number_of_patients":15,"article_patient_number":"7","full_text_available":true,"outcome":"Patient died","surgery":"Unknown","age":"","sex":"","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, fever","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient experienced hypoxic respiratory failure.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11379,8342]},{"id":6628,"regimens":[{"id":13226,"duration":{"id":7116,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11598,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13226},{"id":11599,"answer":"In a novel combination with another drug","answer_other":"","regimen":13226}],"created":"2020-12-01T01:33:40.311170Z","updated":"2020-12-02T21:40:09.741574Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6628},{"id":13227,"duration":{"id":7117,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":11379,"name":"Baricitinib","url":"cure-api2.ncats.io/v1/drugs/11379","rxNorm_id":null,"notes":null},"use_drug":[{"id":11600,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13227},{"id":11601,"answer":"In a novel combination with another drug","answer_other":"","regimen":13227}],"created":"2020-12-01T01:33:40.318996Z","updated":"2020-12-02T21:40:09.748035Z","dose":"4 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6628}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8693,"answer":"Clinical assessment","answer_other":"","report":6628}],"how_diagnosis":[{"id":14943,"answer":"Clinical assessment","answer_other":"","report":6628},{"id":14944,"answer":"PCR","answer_other":"","report":6628}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4808,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6628}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-12-01T01:33:10.130244Z","updated":"2020-12-02T21:40:09.733077Z","title":"Use of Baricitinib in Patients with Moderate and Severe COVID-19. Case 8.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32597466,"doi":"10.1093/cid/ciaa879","article_url":"https://pubmed.ncbi.nlm.nih.gov/32597466/","pub_year":2020,"published_authors":"Titanji BK\r\nFarley MM\r\nMehta A\r\nConnor-Schuler R\r\nMoanna A\r\nCribbs SK\r\nO'Shea J\r\nDeSilva K\r\nChan B\r\nEdwards A\r\nGavegnano C\r\nSchinazi RF\r\nMarconi VC","article_author_email":"Author email could not be found.","journal":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","abstract":"Cytokine storm and hyperinflammation are associated with increased mortality in COVID-19. In this small uncontrolled cohort of patients with moderate-severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized controlled clinical trials.","article_type":"Original","study_type":"Case Report","number_of_patients":15,"article_patient_number":"8","full_text_available":true,"outcome":"Patient improved","surgery":"Unknown","age":"","sex":"","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, fever","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"This patient experienced a pulmonary embolism during hospitalization for which they received therapeutic anticoagulation.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11379,8342]},{"id":6629,"regimens":[{"id":13228,"duration":{"id":7118,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":11602,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13228},{"id":11603,"answer":"In a novel combination with another drug","answer_other":"","regimen":13228}],"created":"2020-12-01T01:41:51.401844Z","updated":"2020-12-02T21:41:29.664604Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6629},{"id":13229,"duration":{"id":7119,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11604,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13229},{"id":11605,"answer":"In a novel combination with another drug","answer_other":"","regimen":13229}],"created":"2020-12-01T01:41:51.410075Z","updated":"2020-12-02T21:41:29.671143Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6629},{"id":13230,"duration":{"id":7120,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":11379,"name":"Baricitinib","url":"cure-api2.ncats.io/v1/drugs/11379","rxNorm_id":null,"notes":null},"use_drug":[{"id":11606,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13230},{"id":11607,"answer":"In a novel combination with another drug","answer_other":"","regimen":13230}],"created":"2020-12-01T01:41:51.416940Z","updated":"2020-12-02T21:41:29.676611Z","dose":"4 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6629}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8694,"answer":"Clinical assessment","answer_other":"","report":6629}],"how_diagnosis":[{"id":14945,"answer":"Clinical assessment","answer_other":"","report":6629},{"id":14946,"answer":"PCR","answer_other":"","report":6629}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4809,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6629}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-12-01T01:40:56.616441Z","updated":"2020-12-02T21:41:29.656806Z","title":"Use of Baricitinib in Patients with Moderate and Severe COVID-19. Case 9.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32597466,"doi":"10.1093/cid/ciaa879","article_url":"https://pubmed.ncbi.nlm.nih.gov/32597466/","pub_year":2020,"published_authors":"Titanji BK\r\nFarley MM\r\nMehta A\r\nConnor-Schuler R\r\nMoanna A\r\nCribbs SK\r\nO'Shea J\r\nDeSilva K\r\nChan B\r\nEdwards A\r\nGavegnano C\r\nSchinazi RF\r\nMarconi VC","article_author_email":"Author email could not be found.","journal":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","abstract":"Cytokine storm and hyperinflammation are associated with increased mortality in COVID-19. In this small uncontrolled cohort of patients with moderate-severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized controlled clinical trials.","article_type":"Original","study_type":"Case Report","number_of_patients":15,"article_patient_number":"9","full_text_available":true,"outcome":"Patient improved","surgery":"Unknown","age":"","sex":"","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, fever","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"This patient experienced an acute kidney injury while hospitalized.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,11379,8342]},{"id":6630,"regimens":[{"id":13231,"duration":{"id":7121,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":11379,"name":"Baricitinib","url":"cure-api2.ncats.io/v1/drugs/11379","rxNorm_id":null,"notes":null},"use_drug":[{"id":11608,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13231},{"id":11609,"answer":"In a novel combination with another drug","answer_other":"","regimen":13231}],"created":"2020-12-01T01:47:38.429573Z","updated":"2020-12-02T21:42:47.045724Z","dose":"2 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6630},{"id":13232,"duration":{"id":7122,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":11610,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13232},{"id":11611,"answer":"In a novel combination with another drug","answer_other":"","regimen":13232}],"created":"2020-12-01T01:47:38.436800Z","updated":"2020-12-02T21:42:47.051983Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6630},{"id":13233,"duration":{"id":7123,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":11612,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13233},{"id":11613,"answer":"In a novel combination with another drug","answer_other":"","regimen":13233}],"created":"2020-12-01T01:47:38.443355Z","updated":"2020-12-02T21:42:47.057436Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6630},{"id":13234,"duration":{"id":7124,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11614,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13234},{"id":11615,"answer":"In a novel combination with another drug","answer_other":"","regimen":13234}],"created":"2020-12-01T01:47:38.450235Z","updated":"2020-12-02T21:42:47.063214Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6630}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8695,"answer":"Clinical assessment","answer_other":"","report":6630}],"how_diagnosis":[{"id":14947,"answer":"Clinical assessment","answer_other":"","report":6630},{"id":14948,"answer":"PCR","answer_other":"","report":6630}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4810,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6630}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-12-01T01:45:38.674083Z","updated":"2020-12-02T21:42:47.037901Z","title":"Use of Baricitinib in Patients with Moderate and Severe COVID-19. Case 10.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32597466,"doi":"10.1093/cid/ciaa879","article_url":"https://pubmed.ncbi.nlm.nih.gov/32597466/","pub_year":2020,"published_authors":"Titanji BK\r\nFarley MM\r\nMehta A\r\nConnor-Schuler R\r\nMoanna A\r\nCribbs SK\r\nO'Shea J\r\nDeSilva K\r\nChan B\r\nEdwards A\r\nGavegnano C\r\nSchinazi RF\r\nMarconi VC","article_author_email":"Author email could not be found.","journal":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","abstract":"Cytokine storm and hyperinflammation are associated with increased mortality in COVID-19. In this small uncontrolled cohort of patients with moderate-severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized controlled clinical trials.","article_type":"Original","study_type":"Case Report","number_of_patients":15,"article_patient_number":"10","full_text_available":true,"outcome":"Patient improved","surgery":"Unknown","age":"","sex":"","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, fever","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"This patient received baricitinib (4 mg daily for 3 days and then 2 mg daily for 2 days).","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,11379,6675,8342]},{"id":6631,"regimens":[{"id":13235,"duration":{"id":7125,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":11616,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13235},{"id":11617,"answer":"In a novel combination with another drug","answer_other":"","regimen":13235}],"created":"2020-12-01T01:54:43.063637Z","updated":"2020-12-02T21:44:22.225331Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6631},{"id":13236,"duration":{"id":7126,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6675,"name":"Ceftriaxone","url":"cure-api2.ncats.io/v1/drugs/6675","rxNorm_id":null,"notes":null},"use_drug":[{"id":11618,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13236},{"id":11619,"answer":"In a novel combination with another drug","answer_other":"","regimen":13236}],"created":"2020-12-01T01:54:43.071917Z","updated":"2020-12-02T21:44:22.231994Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6631},{"id":13237,"duration":{"id":7127,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11620,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13237},{"id":11621,"answer":"In a novel combination with another drug","answer_other":"","regimen":13237}],"created":"2020-12-01T01:54:43.078507Z","updated":"2020-12-02T21:44:22.237899Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6631},{"id":13238,"duration":{"id":7128,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":11379,"name":"Baricitinib","url":"cure-api2.ncats.io/v1/drugs/11379","rxNorm_id":null,"notes":null},"use_drug":[{"id":11622,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13238},{"id":11623,"answer":"In a novel combination with another drug","answer_other":"","regimen":13238}],"created":"2020-12-01T01:54:43.084861Z","updated":"2020-12-02T21:44:22.243322Z","dose":"4 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6631}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8696,"answer":"Clinical assessment","answer_other":"","report":6631},{"id":8737,"answer":"PCR","answer_other":"","report":6631}],"how_diagnosis":[{"id":14949,"answer":"Clinical assessment","answer_other":"","report":6631},{"id":14950,"answer":"PCR","answer_other":"","report":6631}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4811,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6631}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-12-01T01:53:20.976703Z","updated":"2020-12-02T21:44:22.217501Z","title":"Use of Baricitinib in Patients with Moderate and Severe COVID-19. Case 11.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32597466,"doi":"10.1093/cid/ciaa879","article_url":"https://pubmed.ncbi.nlm.nih.gov/32597466/","pub_year":2020,"published_authors":"Titanji BK\r\nFarley MM\r\nMehta A\r\nConnor-Schuler R\r\nMoanna A\r\nCribbs SK\r\nO'Shea J\r\nDeSilva K\r\nChan B\r\nEdwards A\r\nGavegnano C\r\nSchinazi RF\r\nMarconi VC","article_author_email":"Author email could not be found.","journal":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","abstract":"Cytokine storm and hyperinflammation are associated with increased mortality in COVID-19. In this small uncontrolled cohort of patients with moderate-severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized controlled clinical trials.","article_type":"Original","study_type":"Case Report","number_of_patients":15,"article_patient_number":"11","full_text_available":true,"outcome":"Patient improved","surgery":"Unknown","age":"","sex":"","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, fever","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,11379,6675,8342]},{"id":6632,"regimens":[{"id":13239,"duration":{"id":7129,"approximate_duration":"","dates_unknown":true},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11624,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13239},{"id":11625,"answer":"In a novel combination with another drug","answer_other":"","regimen":13239}],"created":"2020-12-01T02:00:13.193827Z","updated":"2020-12-02T21:45:36.397653Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6632},{"id":13240,"duration":{"id":7130,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":11379,"name":"Baricitinib","url":"cure-api2.ncats.io/v1/drugs/11379","rxNorm_id":null,"notes":null},"use_drug":[{"id":11626,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13240},{"id":11627,"answer":"In a novel combination with another drug","answer_other":"","regimen":13240}],"created":"2020-12-01T02:00:13.206613Z","updated":"2020-12-02T21:45:36.403889Z","dose":"2 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6632}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8697,"answer":"Clinical assessment","answer_other":"","report":6632}],"how_diagnosis":[{"id":14951,"answer":"Clinical assessment","answer_other":"","report":6632},{"id":14952,"answer":"PCR","answer_other":"","report":6632}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4812,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6632}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-12-01T01:59:47.070551Z","updated":"2020-12-02T21:45:36.390121Z","title":"Use of Baricitinib in Patients with Moderate and Severe COVID-19. Case 12.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32597466,"doi":"10.1093/cid/ciaa879","article_url":"https://pubmed.ncbi.nlm.nih.gov/32597466/","pub_year":2020,"published_authors":"Titanji BK\r\nFarley MM\r\nMehta A\r\nConnor-Schuler R\r\nMoanna A\r\nCribbs SK\r\nO'Shea J\r\nDeSilva K\r\nChan B\r\nEdwards A\r\nGavegnano C\r\nSchinazi RF\r\nMarconi VC","article_author_email":"Author email could not be found.","journal":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","abstract":"Cytokine storm and hyperinflammation are associated with increased mortality in COVID-19. In this small uncontrolled cohort of patients with moderate-severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized controlled clinical trials.","article_type":"Original","study_type":"Case Report","number_of_patients":15,"article_patient_number":"12","full_text_available":true,"outcome":"Patient improved","surgery":"Unknown","age":"","sex":"","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, fever","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"Unknown","reminder":false,"when_reminder":"1 week","additional_info":"","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11379,8342]},{"id":6633,"regimens":[{"id":13241,"duration":{"id":7131,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11121,"name":"Vancomycin","url":"cure-api2.ncats.io/v1/drugs/11121","rxNorm_id":11124,"notes":""},"use_drug":[{"id":11628,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13241},{"id":11629,"answer":"In a novel combination with another drug","answer_other":"","regimen":13241}],"created":"2020-12-01T02:10:04.636830Z","updated":"2020-12-02T21:48:09.424143Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6633},{"id":13242,"duration":{"id":7132,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6637,"name":"Cefazolin","url":"cure-api2.ncats.io/v1/drugs/6637","rxNorm_id":null,"notes":null},"use_drug":[{"id":11630,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13242},{"id":11631,"answer":"In a novel combination with another drug","answer_other":"","regimen":13242}],"created":"2020-12-01T02:10:04.645395Z","updated":"2020-12-02T21:48:09.430303Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6633},{"id":13243,"duration":{"id":7133,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9114,"name":"Metronidazole","url":"cure-api2.ncats.io/v1/drugs/9114","rxNorm_id":null,"notes":null},"use_drug":[{"id":11632,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13243},{"id":11633,"answer":"In a novel combination with another drug","answer_other":"","regimen":13243}],"created":"2020-12-01T02:10:04.651855Z","updated":"2020-12-02T21:48:09.435921Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6633},{"id":13244,"duration":{"id":7134,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8971,"name":"Meropenem","url":"cure-api2.ncats.io/v1/drugs/8971","rxNorm_id":null,"notes":null},"use_drug":[{"id":11634,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13244},{"id":11635,"answer":"In a novel combination with another drug","answer_other":"","regimen":13244}],"created":"2020-12-01T02:10:04.658272Z","updated":"2020-12-02T21:48:09.441389Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6633},{"id":13245,"duration":{"id":7135,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11636,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13245},{"id":11637,"answer":"In a novel combination with another drug","answer_other":"","regimen":13245}],"created":"2020-12-01T02:10:04.664393Z","updated":"2020-12-02T21:48:09.447091Z","dose":"","frequency":"","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6633},{"id":13246,"duration":{"id":7136,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":11379,"name":"Baricitinib","url":"cure-api2.ncats.io/v1/drugs/11379","rxNorm_id":null,"notes":null},"use_drug":[{"id":11638,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13246},{"id":11639,"answer":"In a novel combination with another drug","answer_other":"","regimen":13246}],"created":"2020-12-01T02:10:04.670720Z","updated":"2020-12-02T21:48:09.452659Z","dose":"4 mg","frequency":"QD","route":"","severity":"ICU/Critical Care","severity_detail":"","comments":null,"report":6633}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":8698,"answer":"Clinical assessment","answer_other":"","report":6633}],"how_diagnosis":[{"id":14953,"answer":"Clinical assessment","answer_other":"","report":6633},{"id":14954,"answer":"PCR","answer_other":"","report":6633}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Undetermined","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4813,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6633}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"},{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-12-01T02:08:50.252250Z","updated":"2020-12-02T21:48:09.416416Z","title":"Use of Baricitinib in Patients with Moderate and Severe COVID-19. Case 13.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32597466,"doi":"10.1093/cid/ciaa879","article_url":"https://pubmed.ncbi.nlm.nih.gov/32597466/","pub_year":2020,"published_authors":"Titanji BK\r\nFarley MM\r\nMehta A\r\nConnor-Schuler R\r\nMoanna A\r\nCribbs SK\r\nO'Shea J\r\nDeSilva K\r\nChan B\r\nEdwards A\r\nGavegnano C\r\nSchinazi RF\r\nMarconi VC","article_author_email":"Author email could not be found.","journal":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","abstract":"Cytokine storm and hyperinflammation are associated with increased mortality in COVID-19. In this small uncontrolled cohort of patients with moderate-severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized controlled clinical trials.","article_type":"Original","study_type":"Case Report","number_of_patients":15,"article_patient_number":"13","full_text_available":true,"outcome":"Patient's condition was unchanged","surgery":"Unknown","age":"","sex":"","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, fever, pneumonia","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"At the time the treatment was completed","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient underwent mechanical ventilation associated with barotrauma, Pneumomedi astinum Bacterial Pneumonia, C-difficile diarrhea, and methicillin-sensitive Staphylococcus aureus pneumonia in the ICU. They remain hospitalized and requires medical care outside the ICU.","previously_treated":"","flagged":false,"other_coinfections":"staphylococcus aureus pneumonia","disease":630,"drugs":[11379,6637,8342,8971,9114,11121]},{"id":6634,"regimens":[{"id":13247,"duration":{"id":7137,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11121,"name":"Vancomycin","url":"cure-api2.ncats.io/v1/drugs/11121","rxNorm_id":11124,"notes":""},"use_drug":[{"id":11640,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13247},{"id":11641,"answer":"In a novel combination with another drug","answer_other":"","regimen":13247}],"created":"2020-12-01T02:23:40.298039Z","updated":"2020-12-02T21:49:24.077522Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6634},{"id":13248,"duration":{"id":7138,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6642,"name":"Cefepime","url":"cure-api2.ncats.io/v1/drugs/6642","rxNorm_id":null,"notes":null},"use_drug":[{"id":11642,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13248},{"id":11643,"answer":"In a novel combination with another drug","answer_other":"","regimen":13248}],"created":"2020-12-01T02:23:40.305838Z","updated":"2020-12-02T21:49:24.083943Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6634},{"id":13249,"duration":{"id":7139,"approximate_duration":null,"dates_unknown":false},"drug":{"id":9121,"name":"Micafungin","url":"cure-api2.ncats.io/v1/drugs/9121","rxNorm_id":null,"notes":null},"use_drug":[{"id":11644,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13249},{"id":11645,"answer":"In a novel combination with another drug","answer_other":"","regimen":13249}],"created":"2020-12-01T02:23:40.312148Z","updated":"2020-12-02T21:49:24.089802Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6634},{"id":13250,"duration":{"id":7140,"approximate_duration":null,"dates_unknown":false},"drug":{"id":7921,"name":"Fluconazole","url":"cure-api2.ncats.io/v1/drugs/7921","rxNorm_id":null,"notes":null},"use_drug":[{"id":11646,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13250},{"id":11647,"answer":"In a novel combination with another drug","answer_other":"","regimen":13250}],"created":"2020-12-01T02:23:40.318289Z","updated":"2020-12-02T21:49:24.095437Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6634},{"id":13251,"duration":{"id":7141,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11648,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13251},{"id":11649,"answer":"In a novel combination with another drug","answer_other":"","regimen":13251}],"created":"2020-12-01T02:23:40.325026Z","updated":"2020-12-02T21:49:24.101166Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6634},{"id":13252,"duration":{"id":7142,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":11379,"name":"Baricitinib","url":"cure-api2.ncats.io/v1/drugs/11379","rxNorm_id":null,"notes":null},"use_drug":[{"id":11650,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13252},{"id":11651,"answer":"In a novel combination with another drug","answer_other":"","regimen":13252}],"created":"2020-12-01T02:23:40.331558Z","updated":"2020-12-02T21:49:24.106869Z","dose":"4 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6634}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14955,"answer":"Clinical assessment","answer_other":"","report":6634},{"id":14956,"answer":"PCR","answer_other":"","report":6634}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4814,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6634}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-12-01T02:21:34.142361Z","updated":"2020-12-02T21:49:24.069720Z","title":"Use of Baricitinib in Patients with Moderate and Severe COVID-19. Case 14.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32597466,"doi":"10.1093/cid/ciaa879","article_url":"https://pubmed.ncbi.nlm.nih.gov/32597466/","pub_year":2020,"published_authors":"Titanji BK\r\nFarley MM\r\nMehta A\r\nConnor-Schuler R\r\nMoanna A\r\nCribbs SK\r\nO'Shea J\r\nDeSilva K\r\nChan B\r\nEdwards A\r\nGavegnano C\r\nSchinazi RF\r\nMarconi VC","article_author_email":"Author email could not be found.","journal":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","abstract":"Cytokine storm and hyperinflammation are associated with increased mortality in COVID-19. In this small uncontrolled cohort of patients with moderate-severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized controlled clinical trials.","article_type":"Original","study_type":"Case Report","number_of_patients":15,"article_patient_number":"14","full_text_available":true,"outcome":"Patient died","surgery":"Unknown","age":"","sex":"","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, fever","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient experienced a candidemia infection and respiratory tract infection.","previously_treated":"","flagged":false,"other_coinfections":"candidemia infection","disease":630,"drugs":[11379,6642,7921,8342,9121,11121]},{"id":6635,"regimens":[{"id":13253,"duration":{"id":7143,"approximate_duration":null,"dates_unknown":false},"drug":{"id":6122,"name":"Azithromycin","url":"cure-api2.ncats.io/v1/drugs/6122","rxNorm_id":null,"notes":null},"use_drug":[{"id":11652,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13253},{"id":11653,"answer":"In a novel combination with another drug","answer_other":"","regimen":13253}],"created":"2020-12-01T02:30:39.635594Z","updated":"2020-12-02T21:50:38.836007Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6635},{"id":13254,"duration":{"id":7144,"approximate_duration":null,"dates_unknown":false},"drug":{"id":11121,"name":"Vancomycin","url":"cure-api2.ncats.io/v1/drugs/11121","rxNorm_id":11124,"notes":""},"use_drug":[{"id":11654,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13254},{"id":11655,"answer":"In a novel combination with another drug","answer_other":"","regimen":13254}],"created":"2020-12-01T02:30:39.643890Z","updated":"2020-12-02T21:50:38.842203Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6635},{"id":13255,"duration":{"id":7145,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8971,"name":"Meropenem","url":"cure-api2.ncats.io/v1/drugs/8971","rxNorm_id":null,"notes":null},"use_drug":[{"id":11656,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13255},{"id":11657,"answer":"In a novel combination with another drug","answer_other":"","regimen":13255}],"created":"2020-12-01T02:30:39.651166Z","updated":"2020-12-02T21:50:38.847794Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6635},{"id":13256,"duration":{"id":7146,"approximate_duration":"5 days","dates_unknown":true},"drug":{"id":11379,"name":"Baricitinib","url":"cure-api2.ncats.io/v1/drugs/11379","rxNorm_id":null,"notes":null},"use_drug":[{"id":11658,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13256},{"id":11659,"answer":"In a novel combination with another drug","answer_other":"","regimen":13256}],"created":"2020-12-01T02:30:39.658508Z","updated":"2020-12-02T21:50:38.853508Z","dose":"2 mg","frequency":"QD","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6635},{"id":13257,"duration":{"id":7147,"approximate_duration":null,"dates_unknown":false},"drug":{"id":8342,"name":"Hydroxychloroquine","url":"cure-api2.ncats.io/v1/drugs/8342","rxNorm_id":null,"notes":null},"use_drug":[{"id":11660,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":13257},{"id":11661,"answer":"In a novel combination with another drug","answer_other":"","regimen":13257}],"created":"2020-12-01T02:30:39.664997Z","updated":"2020-12-02T21:50:38.859066Z","dose":"","frequency":"","route":"","severity":"Inpatient","severity_detail":"","comments":null,"report":6635}],"site_of_infection":[],"specific_site":[],"how_outcome":[],"how_diagnosis":[{"id":14957,"answer":"Clinical assessment","answer_other":"","report":6635},{"id":14958,"answer":"PCR","answer_other":"","report":6635}],"author_username":"Cure Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Other Healthcare Professional","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Deteriorated","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":4815,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":6635}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":550,"name":"Respiratory Tract Infections"}],"races":[],"created":"2020-12-01T02:29:43.426729Z","updated":"2020-12-02T21:50:38.827432Z","title":"Use of Baricitinib in Patients with Moderate and Severe COVID-19. Case 15.","status":"Approved","anonymous":false,"published":true,"pubmed_id":32597466,"doi":"10.1093/cid/ciaa879","article_url":"https://pubmed.ncbi.nlm.nih.gov/32597466/","pub_year":2020,"published_authors":"Titanji BK\r\nFarley MM\r\nMehta A\r\nConnor-Schuler R\r\nMoanna A\r\nCribbs SK\r\nO'Shea J\r\nDeSilva K\r\nChan B\r\nEdwards A\r\nGavegnano C\r\nSchinazi RF\r\nMarconi VC","article_author_email":"Author email could not be found.","journal":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","abstract":"Cytokine storm and hyperinflammation are associated with increased mortality in COVID-19. In this small uncontrolled cohort of patients with moderate-severe COVID-19, treatment with baricitinib plus hydroxychloroquine was associated with recovery in 11 of 15 patients. Baricitinib for the treatment of COVID-19 should be further investigated in randomized controlled clinical trials.","article_type":"Original","study_type":"Case Report","number_of_patients":15,"article_patient_number":"15","full_text_available":true,"outcome":"Patient died","surgery":"Unknown","age":"","sex":"","ethnicity":null,"country_contracted":"United States","country_treated":"United States","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"","pregnant":false,"unknown":true,"site_of_disease":"lungs","clinical_syndrome":"respiratory tract infection, fever","severity":null,"prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"No","reminder":false,"when_reminder":"1 week","additional_info":"This patient experienced atrial fibrillation and cariogenic shock.","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[6122,11379,8342,8971,11121]}]